BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bavituximab: Phase II started

Peregrine began an open-label Phase II trial to compare weekly 0.3 and 3 mg/kg IV bavituximab plus ribavirin vs. Pegasys peginterferon alfa-2a plus ribavirin...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >